Literature DB >> 15679052

Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties.

James M Rae1, Susan J Ramus, Mark Waltham, Jane E Armes, Ian G Campbell, Robert Clarke, Robert J Barndt, Michael D Johnson, Erik W Thompson.   

Abstract

Recently, the tissue origin of MDA-MB-435 cell line has been the subject of considerable debate. In this study, we set out to determine whether MDA-MB-435-DTP cells shown to express melanoma-specific genes were identical to various other MDA-MB-435 cell stocks worldwide. CGH-microarray, genetic polymorphism genotyping, microsatellite fingerprint analysis and/or chromosomal number confirmed that the MDA-MB-435 cells maintained at the Lombardi Comprehensive Cancer Center (MDA-MB-435-LCC) are almost identical to the MDA-MB-435-DTP cells, and showed a very similar profile to those obtained from the same original source (MD Anderson Cancer Center) but maintained independently (MDA-MB-435-PMCC). Gene expression profile analysis confirmed common expression of genes among different MDA-MB-435-LCC cell stocks, and identified some unique gene products in MDA-MB-435-PMCC cells. RT-PCR analysis confirmed the expression of the melanoma marker tyrosinase across multiple MDA-MB-435 cell stocks. Collectively, our results show that the MDA-MB-435 cells used widely have identical origins to those that exhibit a melanoma-like gene expression signature, but exhibit a small degree of genotypic and phenotypic drift.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15679052     DOI: 10.1007/s10585-004-3759-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  28 in total

1.  Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line.

Authors:  Shankar Sellappan; Rebecca Grijalva; Xiaoyan Zhou; Wentao Yang; Menashe Bar Eli; Gordon B Mills; Dihua Yu
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

2.  LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.

Authors:  Erik W Thompson; Mark Waltham; Susan J Ramus; Anne-Marie Hutchins; Jane E Armes; Ian G Campbell; Elizabeth D Williams; Phillip R Thompson; James M Rae; Michael D Johnson; Robert Clarke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  Phenotypic drift and heterogeneity in response of metastatic mammary adenocarcinoma cell clones to adriamycin, 5-fluoro-2'-deoxyuridine and methotrexate treatment in vitro.

Authors:  D R Welch; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

4.  Multiple phenotypic divergence of mammary adenocarcinoma cell clones. II. Sensitivity to radiation, hyperthermia and FUdR.

Authors:  D R Welch; D P Evans; S P Tomasovic; L Milas; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1984 Oct-Dec       Impact factor: 5.150

5.  Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

Authors:  R Cailleau; M Olivé; Q V Cruciger
Journal:  In Vitro       Date:  1978-11

6.  A protein expression database for the molecular pharmacology of cancer.

Authors:  T G Myers; N L Anderson; M Waltham; G Li; J K Buolamwini; D A Scudiero; K D Paull; E A Sausville; J N Weinstein
Journal:  Electrophoresis       Date:  1997 Mar-Apr       Impact factor: 3.535

Review 7.  Analyzing the metastatic phenotype.

Authors:  J E Price
Journal:  J Cell Biochem       Date:  1994-09       Impact factor: 4.429

8.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

9.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

10.  Molecular cytogenetic analysis of breast cancer cell lines.

Authors:  J M Davidson; K L Gorringe; S F Chin; B Orsetti; C Besret; C Courtay-Cahen; I Roberts; C Theillet; C Caldas; P A Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  36 in total

1.  LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines.

Authors:  Erik W Thompson; Mark Waltham; Susan J Ramus; Anne-Marie Hutchins; Jane E Armes; Ian G Campbell; Elizabeth D Williams; Phillip R Thompson; James M Rae; Michael D Johnson; Robert Clarke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract.

Authors:  Erika Rosivatz; Karl-Friedrich Becker; Elisabeth Kremmer; Christina Schott; Kareen Blechschmidt; Heinz Höfler; Mario Sarbia
Journal:  Virchows Arch       Date:  2005-11-17       Impact factor: 4.064

3.  Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications.

Authors:  Subha Philip; Srividya Swaminathan; Sergey G Kuznetsov; Sreenivas Kanugula; Kajal Biswas; Suhwan Chang; Natalia A Loktionova; Diana C Haines; Philipp Kaldis; Anthony E Pegg; Shyam K Sharan
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

4.  Spheroid-based drug screen: considerations and practical approach.

Authors:  Juergen Friedrich; Claudia Seidel; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

5.  DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype.

Authors:  Aparna Mitra; Mitchell E Menezes; Lalita A Shevde; Rajeev S Samant
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

6.  In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Authors:  Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

7.  Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

Authors:  Brandon J Metge; Andra R Frost; Judy A King; Donna Lynn Dyess; Danny R Welch; Rajeev S Samant; Lalita A Shevde
Journal:  Clin Exp Metastasis       Date:  2008-06-20       Impact factor: 5.150

Review 8.  Influence of diet on metastasis and tumor dormancy.

Authors:  Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

9.  Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition.

Authors:  Yvonne L Chao; Christopher R Shepard; Alan Wells
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

10.  Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.

Authors:  William Cruz-Munoz; Shan Man; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.